13F Holdings
中文EN

ABT ABBOTT LABORATORIES

Pharmaceutical Preparations · NYSE · SEC CIK 1800 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY10.0%
TTM net income YoY-66.4%
TTM EPS YoY-66.2%
Revenue 3-yr CAGR6.5%
Net income 3-yr CAGR-3.1%

Margins

Gross margin56.9%
Operating margin13.8%
Net margin9.7%
FCF margin14.0%
EBITDA margin17.0%

Returns

ROE9.2%
ROA4.9%
ROIC (approx.)7.1%
Asset turnover0.50x

Leverage & solvency

Liabilities / assets52.3%
Debt / equity0.61x
Current ratio1.45x
Interest coverage6.68x

Cash quality & payout

Operating cash flow / net income1.88x
Accruals ratio-4.3%
Payout ratio92.0%
Capex / revenue4.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$44.33B$41.95B$40.11B$43.65B$43.08B
Cost of revenue$19.32B$18.71B$17.98B$19.14B$18.54B
Gross profit$25.01B$23.24B$22.13B$24.51B$24.54B
R&D expense$2.94B$2.84B$2.74B$2.89B$2.74B
SG&A expense$12.33B$11.70B$10.95B$11.25B$11.32B
Operating income$8.05B$6.83B$6.48B$8.36B$8.43B
Interest expense$493.00M$559.00M$637.00M$558.00M$533.00M
Pretax income$8.47B$7.01B$6.66B$8.31B$8.21B
Income tax$1.94B-$6.39B$941.00M$1.37B$1.14B
Net income$6.52B$13.40B$5.72B$6.93B$7.07B
EBITDA$9.49B$8.16B$7.75B$9.62B$9.92B
EPS (basic)3.737.673.283.943.97
EPS (diluted)3.727.643.263.913.94
Dividends declared per share2.402.242.081.92—
Weighted avg. shares (diluted)1.75B1.75B1.75B1.76B1.79B
Balance sheet
Cash & equivalents$8.52B$7.62B$6.90B$9.88B$9.80B
Short-term investments$417.00M$351.00M$383.00M$288.00M$450.00M
Receivables$7.93B$6.92B$6.57B$6.22B$6.49B
Inventory$6.49B$6.19B$6.57B$6.17B$5.16B
Current assets$26.00B$23.66B$22.67B$25.22B$24.24B
PP&E, net$11.82B$10.66B$10.15B$9.16B$8.96B
Goodwill$24.04B$23.11B$23.68B$22.80B$23.23B
Intangibles$5.53B$6.65B$8.81B$10.45B$12.74B
Total assets$86.71B$81.41B$73.21B$74.44B$75.20B
Current liabilities$16.50B$14.16B$13.84B$15.49B$13.11B
Short-term debt$3.03B$1.50B$1.08B$2.25B$0
Long-term debt$9.90B$12.62B$13.60B$14.52B$17.30B
Total debt$12.93B$14.12B$14.68B$16.77B$17.30B
Total liabilities$33.94B$33.51B$34.39B$37.53B$39.17B
Shareholders' equity$52.13B$47.66B$38.60B$36.69B$35.80B
Net debt$4.41B$6.51B$7.78B$6.89B$7.50B
Cash flow statement
Operating cash flow$9.57B$8.56B$7.26B$9.58B$10.53B
Capital expenditure$2.17B$2.21B$2.20B$1.78B$1.89B
Free cash flow$7.39B$6.35B$5.06B$7.80B$8.65B
Investing cash flow-$2.42B-$2.34B-$3.13B-$1.74B-$2.01B
Financing cash flow-$6.31B-$5.40B-$7.09B-$7.64B-$5.49B
Depreciation & amortization$1.43B$1.34B$1.28B$1.25B$1.49B
Stock-based compensation$664.00M$673.00M$644.00M$685.00M$640.00M
Dividends paid$4.12B$3.84B$3.56B$3.31B$3.20B
Share buybacks$893.00M$1.29B$1.23B$3.79B$2.30B

Free plan shows the latest 5 periods; Pro shows all 19 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.